Related Experiment Video
Updated: Jul 25, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Clinic dosing of beta blockers in chronic heart failure
T M Ramahi1, R Rohlfs, N Sheynberg
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510.
Insights
Initiating beta-blocker therapy for chronic heart failure patients does not require a 1-hour observation period. Stable patients can safely start and adjust beta-blocker doses at home, reducing healthcare costs.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta blockers are crucial for improving survival and reducing morbidity in chronic heart failure (CHF).
- Current guidelines mandate a 1-hour observation post-initiation or up-titration of beta-blocker therapy.
- This observation period may increase healthcare costs and limit beta-blocker utilization.
Purpose of the Study:
- To evaluate the necessity and safety of the 1-hour in-clinic observation period for beta-blocker therapy in CHF patients.
- To determine if beta-blockers can be safely initiated and up-titrated at home for stable CHF patients.
Main Methods:
- Retrospective analysis of 130 in-clinic observation periods for 34 stable CHF patients on carvedilol.
- Patients had severe left ventricular dysfunction (mean ejection fraction 0.22±0.09) and were in functional class 2.5±0.6.
- Blood pressure and heart rate were monitored hourly during 1-2 hour observation periods post-initiation or dose increase.
Main Results:
- No patients required a dose reduction during the in-clinic observation periods.
- A slight but statistically significant decrease in blood pressure was observed 1 hour post-dosing (p < 0.001).
- Adverse events requiring dose decrease or discontinuation occurred days after dosage increases, not during clinic observation.
Conclusions:
- The 1-hour in-clinic observation period for beta-blocker initiation/up-titration in stable CHF patients is not essential.
- Properly selected and evaluated stable CHF patients can safely initiate and up-titrate beta-blockers at home.
- Home-based titration can potentially reduce healthcare expenses and improve access to beta-blocker therapy.
Abstract:
Beta blockers improve survival and reduce morbidity of patients with chronic heart failure. Stringent dosing guidelines calling for a 1-hour observation period after initiation or up-titration of beta-blocker therapy might limit the use of beta blockers and increase the expense involved. This study was conducted to determine the usefulness of this observation period. Data were collected from 130 in-clinic postdosing observation periods for 34 stable chronic heart failure patients started on carvedilol. The mean left ventricular ejection fraction was 0.22±0.09, and the mean functional class was 2.5±0.6. No patient had greater than first-degree heart block. Carvedilol was started at 3.125 or 6.25 mg b.i.d., and the dose was doubled every 1-3 weeks. All patients were observed for 1-2 hours after initiation or dosage increase, and blood pressure and heart rate were measured hourly. The maximal daily dose was 50±31 mg. In none of the observation periods was there a decrease in the dose of beta blockers administered in the clinic. The predosing mean blood pressure was 110±15/71±10 mm Hg, and the mean heart rate was 78±13 bpm; the 1-hour postdosing mean blood pressure was 101±14/67±10 mm Hg (p is less than 0.001), and the heart rate was 78±13 bpm. The dose was decreased in six patients and medication was discontinued in three, all consequent to symptoms reported several days after dosage increase. Beta blockers can be safely initiated and up-titrated at home in properly selected and evaluated stable patients with chronic heart failure and severe left ventricular dysfunction resulting in mild or moderate impairment of functional capacity. (c)2001 by CHF, Inc.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
